SUMMARY
Halothane-associated hepatitis in children occurs with an incidence of less than 1 in 82,000. I In adults the incidence is 1 in 10,000. 2 This difference in incidence of halothane-associated hepatitis between children and adults has never been adequately explained although it has been postulated that it may be due to either a quantitative or qualitative difference in halothane metabolism. In 1975, Cohen 3 studied eight adult patients receiving halothane and identified TF AE as a major urinary metabolite. The authors speculated that there was covalent binding of the oxidative metabolite of halothane, trifluoroacetyl chloride, with the phosphatidylethanolamine moiety of cephalin, a normal constituent of all cell membranes. This reacton may have a direct toxic effect on the hepatocyte. Enzymatic cleavage of the necrotic hepatocyte would release TF AE into the plasma with subsequent urinary excretion. In adults irreversibly bound halothane metabolites have been demonstrated in the liver both chemically and autoradiographically following halothane anaesthesia. 4 ,5 It is possible that children do not metabolise halothane via this mechanism and this may explain why children are less susceptible to halothaneassociated hepatitis than are adults. Our study was designed to measure TF AE in the urine of children following halothane anaesthesia and to assess whether it is a major urinary metabolite of halothane.
PATIENTS AND METHODS

N-Trifluoroacetyl-ethanolamine identification
TFAE was prepared from ethyl-trifluoroacetate and ethanolamine in chloroform solution (V.S. Patent Specification 1, 123, 672). The compound was analysed by nuclear magnetic resonance spectroscopy eH NMR,13 C NMR) and mass spectrometry. Spectral data were consistent with the titled structure CF 3 CONHCH 2 CH 2 0H (Tables  1 and 2) .
TF AE measurement
Anion exchange columns were prepared by packing a 2 m1 syringe barrel with a plug of glass wool and pouring in a slurry of AGI-X2 (Bio-rad, Richmond California) in water to obtain 1 cc of the resin. The resin column was washed with 3 X 1 ml water. Urine was centrifuged, 0.1 mllayered onto the column and washed through with 1.9 ml water. The eluate was collected and stored at -20°C until analysis. TF AE was analysed by high pressure liquid chromatography (HPLC). The mobile phase was 25 mM aqueous sodium phosphate pH 7.0 at a flow rate of 1.0 ml.min -1. The equipment consisted of a Waters M6000 pump, Rheodyne injector and Waters 480 variable wavelength UV detector. The compound was measured by absorption of the amide group in the compound at 205 nm. To achieve resolution of this very polar compound, several Brownlee reverse phase columns were used in series, first a Newguard 1.5 cm X 3.2 mm RP-18 guard column, second a 25 cm X 4.6 mm RP-18 Spheri-5 column and third a 10 cm X 4.6 mm RP-18 Spheri-5 cartridge. These were linked together with 5 cm pieces of Alltech 1/16" X 0.01" pre-cut stainless steel tubing using Activon/ Upchurch fingertight fittings and equivalent to a 35 cm reverse-phase column. 20 ~l of sample or standard was injected giving a retention time of7.8 minutes.
The limit of detection was 0.3 ~M in the extracted samples, equivalent to 6.0 ~M in the original urine. Peak height was linear with concentrations from 0.3 ~M to 1.0 mM. Standards of 640 ~M and 64 ~M TF AE extracted through the system gave recoveries of 99% and 96%. The coefficient of variation for five replicate determinations of an extracted 640 ~ standard was 2.8%. Separation of TFAE from major UV-absorbing constituents of urine was confirmed by comparing the chromatograms of unspiked urine and urine spiked with TFAE ( Figure 1 ).
Patient details
Six children were included in the study with one child being studied twice. Five patients were fit children having elective surgery. Patient six, a tenyear-old boy had cystic fibrosis, chronic lung disease and biopsy-proven liver disease. Full patient details are given in Table 3 . Halothane 1 % v/v was administered from a Mark III fluotec vapouriser for one hour in an inspiratory gas mixture of oxygen 2 litre.min -1 and nitrous oxide 4 litre.min -1. After the cessation of halothane, anaesthesia was mainained with nitrous oxide and oxygen with bolus doses of 2 mg.kg -1 thiopentone given if required. Inspiratory gas samples from the fresh gas line were collected every fifteen minutes into gas-tight glass syringes (SGE Ringwood, Victoria, Australia) and halothane concentration measured by gas chromatography. Expiratory minute ventilation was measured with a Wright respirometer (BOC Healthcare, Surrey, England). Residual halothane in expired gas was measured by gas chromatography. Halothane uptake was calculated from the patient's inspiratory and expiratory halothane concentration and minute ventilation. The experimental method has been described in detail elsewhere. 5 Urine was collected continuously until the patient left hospital and stored at -4°C until analysed for TFAE. Length of urine collections varied from three to eight days. Details ofTFAE excretion are shown in Table 4 . On four of the seven occasions that halothane metabolism was investigated a HPLC peak with the same retention time as TF AE was identified in preoperative urine samples. This peak was due to an unidentified interfering substance. In calculating TF AE excretion the assumption was made that all UV absorbing material with a retention time at 7.8 minutes was TFAE and no correction was made for interfering substances in the control urine. The results obtained represent the upper possible limit of TFAE excretion.
Total urinary excretion varied from 8 to 40
~ moles and 0.09 ± 0.07% of the absorbed halothane was metabolised to TF AE.
DISCUSSION
A proposed oxidative metabolic pathway of halothane which has the potential to cause liver cell necrosis is shown in Figure 2 . In 1975 Cohen and colleagues 4 reported a study of eight adult patients following intravenous radiolabelled halothane administration and found by counting urinary radioactivity that TF AE constituted 20% of urinary halothane metabolites. In this paper a quantitative technique for measuring TF AE was not described. These authors postulated that the halothane metabolite trifluoroacetyl chloride combined by a nucleophilic substitution reaction with the phosphatidylethanolamine component of the hepatic cell membrane causing cell necrosis. Enzymatic breakdown of the necrotic cell membrane resulting in TF AE release into the serum with subsequent urinary excretion.
Our study was designed to develop a measurement technique for TF AE, and then to confirm or deny whether TF AE is a major urinary metabolite of halothane in normal children. An initial difficulty was that TFAE was not commercially available. A quantity of TFAE was synthetized from ethyl-trifluoroacetate and ethanolamine and its authenticity validated using nuclear magnetic resonance and mass spectroscopy. A direct measurement technique for TFAE was devised using HPLC with ultraviolet detection. In some patients an interfering substance was identified in preoperative urine samples which had the same UV absorption spectra as TF AE. Despite trying different compositions of mobile phase solutions with varying pH and ionic strength, the UV absorption peak of the trace level of interfering substance could not be separated from that of TF AE. In our study of six children aged from 14-119 months, urinary TF AE constituted O.O? ± 0.07% or less of the absorbed halothane. U nne samples from the six patients included in the present study were analysed for TF A and the results published. 5 In the children studied the urinary TF A: TF AE ratio was greater than 100: 1, indicating that TF AE is not a major urinary metabolite. It is postulated that patients who develop hepatic cell necrosis following halothane either metabolise halothane differently from normal patients producing a toxic metabolite or produce an antibody or antibodies to a normal halothane metabolite -cell membrane combination. 6 If covalent binding of trifluoracetyl chloride to the phosphatidyl ethanolamine component of the hepatic cell membrane played a role in halothane hepatitis, then in these patients TF AE excretion should be increased. A further study is planned to investigate urinary excretion of TF AE in patients who develop unexplained hepatitis following halothane. If it was shown that TFAE excretion is not increased in these patients, it would suggest that covalent binding of trifluoroacetyl chloride reactive intermediates to cell membrane phosphatidylethanolamine does not have an etiological role in the production of halothane induced liver injury,
